Rigel stock dives on another drug study failure

Rigel Pharmaceuticals Inc.'s already-shortened list of potential drug treatments lost two more. An experimental treatment for dry eye disease, called R-348, failed a mid-stage trial, the South San Francisco company (NASDAQ: RIGL) said Wednesday...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.